First-ever bio-generic drug doesn’t help Novartis shares
March 06, 2015 at 15:10 PM EST
Getting the U.S. Food and Drug Administration’s first-ever approval for a biosimilar didn’t do much for Novartis shares in early trading Friday.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.